PRISM BioLab Co.,LTD (JPX: 206A.T) AI-Powered Stock Analysis
See how PRISM BioLab Co.,LTD scores across key metrics like financial growth, valuation, and market position on the JPX, using AI-driven evaluation.
206A.T●JPX
HealthcareBiotechnology
¥168.00
¥2.00(1.18%)
Japanese Market opens in 10h 49m
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerPRISM BioLab Co.,LTD (JPX: 206A.T) Stock Overall Grade
PRISM BioLab Co.,LTD's grade for its JPX listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to PRISM BioLab Co.,LTD's overall JPX stock rating.
Forecast
B+Score
73/100Financial Growth
C+Score
50/100Fundamental Growth
CScore
48/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100PRISM BioLab Co.,LTD (JPX: 206A.T) AI-Powered Stock Analysis
On the JPX, 206A.T demonstrates Good performance with an overall Forecast Score of 73/100 (B+), reflecting high confidence in its potential. Financial Growth (50/100, C+) and Fundamental Growth (48/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the JPX-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(JPX: 206A.T) Component Analysis Explained
Understand the key factors behind each PRISM BioLab Co.,LTD (JPX: 206A.T) stock grade, including financials, comparisons, and forecasts.